N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=62 Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Phase 2 N=20 Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
N/A N=122 Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Barrett Syndrome · Barrett's Syndrome · Barrett's Esophagus
Primary: Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of…
Phase 2 N=515 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gastric Adenocarcinoma · Esophageal Cancer · Hepatocellular Carcinoma
Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…
Phase 1 N=22 Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients
Carcinoma
Primary: the Number of Lymph Nodes: 1. Identified Within Each Lymph Node Group, 2.Located Within the Submandibular Gland, and 3. Within the Fibrofatty Contents Lying Deep to the…
N/A N=66 In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors
Pancreatic Cysts
Primary: Sensitivity — 59 percentage of participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=1,553 Studies of Elevated Parathyroid Activity
Hyperparathyroidism · Hypercalcemia · Parathyroid Neoplasm
Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants
N/A N=55 Ultrasound Elastography in Imaging Patients With Thyroid Nodules
Malignant Thyroid Gland Neoplasm · Thyroid Gland Nodule
Primary: Stiffness of Thyroid Nodules as Measured by Elastography — 2.7; 3.8; 2.7 meters/second
N/A N=9 Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
Malignant Melanoma · Head and Neck Cancer
Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
N/A N=93 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia
Oral Epithelial Dysplasia, Mild or Moderate Grade
Primary: The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia — 32; 46 participants
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
N/A N=367 Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
Gastric Cancer, Gastroesophageal Junction Cancer
Primary: Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments — 0.69 kappa coefficient…
N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
Phase 2 N=39 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
High-grade Salivary Gland Carcinoma · High-grade Salivary Gland Mucoepidermoid Carcinoma · Low-grade Salivary Gland Carcinoma
Primary: Objective Response Rates (Partial and Complete Responses) — 0 participants
Phase 2 N=103 A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Ovarian Cancer · Non Small Cell Lung Cancer · Prostate Cancer
Primary: Percentage of Participants With a Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 0 percentage of participants
Phase 2 N=341 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Neuroendocrine Tumors · Von Hippel-Lindau Syndrome · Hippel-Lindau Disease
Primary: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan — 847 Number of lesions
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
N/A N=32 Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Phase 2 N=55 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Malignant Salivary Gland Neoplasm · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Response Rate — 0; 0; 1; 0 participants
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Phase 1 N=65 Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
Neoplasms
Primary: Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs) — 3; 3; 14; 3 Participants
Phase 2 N=23 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Neuroendocrine Tumors · Carcinoma, Small Cell Lung · Neuroendocrine Carcinoma
Primary: Phase 1: Maximum Tolerated Dose of PEN-221 and Recommended Phase 2a Dose (RP2D) — 18.0 mg
Phase 2 N=44 Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
Locally Advanced Epithelioid Hemangioendothelioma · Metastatic Epithelioid Hemangioendothelioma · Unresectable Epithelioid Hemangioendothelioma
Primary: Objective Response Rate — 9.5 Percentage
Phase 2 N=80 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
Adenocarcinoma
Primary: Overall Survival — 15.7; 9.0 months — p=0.0024
Phase 2 N=100 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Early Phase 1 N=18 Using MASL to Combat Oral Cancer
Squamous Cell Carcinoma of Head and Neck
Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05